ArticleProteomics2026
Enabling Variant Proteogenomic Assay Development Through a Peptide Target Selection Pipeline and Web Application.
Article in Proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The quantification of key protein variants can guide precision oncology to enable better identification of driver mutations. Bottom-up assays infer parent protein levels through the quantification of surrogate peptides. Assay methods designed for absolute quantification of protein variants, such as multiple reaction monitoring mass spectrometry (MRM-MS), can achieve quantitation with high precision and specificity. Bottom-up approaches rely on proper selection of suitable surrogate proteogenotypic peptide targets to quantify protein variants of interest. To this end, we developed an R-based bioinformatics pipeline to predict and evaluate variant-specific peptides. The workflow generates variant protein sequences from wild-type sequences and mutations encoded in the Human Genome Variation Society (HGVS) recommended nomenclature, performs in-silico tryptic digestion, and identifies both variant and corresponding wild-type peptides. Each peptide is evaluated by 37 selection criteria to determine suitability as MRM targets. To assess the strictness of these criteria, we applied all protein-altering mutations from the NCI-Genomic Data Commons (GDC) and COSMIC to our pipeline. Of the peptides outputted, 5% satisfied all defined criteria, representing the highest confidence candidates for assay development. We developed a database and web application from NCI-GDC generated peptides for searching, filtering, and downloading. Another web application was developed to provide access to our pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.